NEWS Ethics Approval of a Phase 1b Clinical Trial Investigating Deflexifol™ 1st Line Treatment of Unresectable Metastatic Colorectal CancerApril 9, 2024Read MoreDeflexifol™ Clinical Data Presented at the 2024 ASCO Gastrointestinal Cancers SymposiumFebruary 2, 2024Read MoreAppointment of Mr Iain Ross as Non-Executive DirectorOctober 9, 2023Read MoreFirst Patient Treated in the Deflexifol™ at Relapse Trial in Paediatric Brain CancerSeptember 5, 2023Read MoreAllarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion DiagnosticsJuly 31, 2023Read MoreCommencement of Deflexifol™ Trial in Paediatric Brain CancerJune 6, 2023Read MoreSuccessful Completion of Deflexifol™ Dose Ranging StudyJune 1, 2023Read MoreFivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos HealthMay 26, 2023Read MoreFivepHusion Announces Successful Type C Meeting with the FDA regarding the Deflexifol™ Clinical Development, CMC and Regulatory Paths for mCRCJanuary 18, 2023Read MoreStrategic Collaboration with the University of South Australia, Successful Over-Subscribed Capital Raising and Non-Dilutive FundingNovember 30, 2022Read MoreIndependent Data Safety Monitor Recommends Deflexifol™ Dose Escalation after Review of Promising Clinical ResultsJanuary 31, 2022Read MoreFivepHusion Announces Establishment of an Independent Expert Clinical Advisory BoardJanuary 18, 2022Read More
